Anika Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported a 4.95% ownership stake in Anika Therapeutics Inc. as of June 30, 2026.
NASDAQ
BlackRock Portfolio Management LLC has disclosed a beneficial ownership of 544,710 shares, representing 4.1% of the outstanding common stock of Anika Therapeutics Inc.
NASDAQ
Vanguard Capital Management has reported a beneficial ownership of 5.19% in Anika Therapeutics Inc., holding 695,697 shares as of March 31, 2026.
NASDAQ
The Vanguard Group has reported 0% beneficial ownership of Anika Therapeutics Inc. common stock following an internal realignment.
NASDAQ
Trigran Investments and its principals have filed an amended Schedule 13G, reporting a 1.2% beneficial ownership stake in Anika Therapeutics, Inc. as of December 31, 2025.
NASDAQ
Trigran Investments and its principals have disclosed an 11.2% beneficial ownership stake in Anika Therapeutics, Inc., reserving the right for director nominations.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.5% Stake in Anika Therapeutics
BlackRock Portfolio Management LLC has reported a 5.5% beneficial ownership stake in Anika Therapeutics Inc., holding 793,359 common shares.
NASDAQ
SCHEDULE 13G/A: BlackRock Increases Stake in Anika Therapeutics to 6.8%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.8% beneficial ownership stake in Anika Therapeutics Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 10.6% Stake in Anika Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 10.6% of Anika Therapeutics Inc.'s common stock as of December 31, 2024.
NASDAQ
Dimensional Fund Advisors LP has filed an amended Schedule 13G, reporting a 4.5% passive beneficial ownership stake in Anika Therapeutics Inc. as of December 31, 2024.